Table 2.
The comparisons of clinicopathological characteristics between ER + SR and ER-alone treatments in high-risk group with LVI(+) and/or VM(+)
| ER + SR | ER-alone |
p value (χ2 test) |
||
|---|---|---|---|---|
| (n = 19) | (n = 18) | |||
| Age | ||||
| Median [IQR] | 62.00 [55.00, 63.50] | 61.00 [54.00, 69.75] | 0.522# | |
| Sex | ||||
| Female | 1 (5.3%) | 2 (11.1%) | 0.604^ | |
| Male | 18 (94.7%) | 16 (88.9%) | ||
| SMI ≥ 200 μm | ||||
| Negative | 0 (0.0%) | 4 (22.2%) | 0.046^ | |
| Positive | 19 (100.0%) | 14 (77.8%) | ||
| VM | ||||
| Negative | 9 (47.4%) | 15 (83.3%) | 0.038^ | |
| Positive | 10 (52.6%) | 3 (16.7%) | ||
| LVI | ||||
| Negative | 6 (31.6%) | 2 (11.1%) | 0.232^ | |
| Positive | 13 (68.4%) | 16 (88.9%) | ||
| PD | ||||
| Negative | 9 (47.4%) | 9 (50.0%) | 1.000 | |
| Positive | 10 (52.6%) | 9 (50.0%) | ||
| Location | ||||
| Upper | 1 (5.3%) | 2 (11.1%) | 0.048 | |
| Middle | 1 (5.3%) | 6 (33.3%) | ||
| Lower | 17 (89.5%) | 10 (55.6%) | ||
| Concurrent LNM | ||||
| Negative | 9 (47.4%) | NA | NA | |
| Positive | 10 (52.6%) | NA | ||
| Post-resection LNM | ||||
| Negative | 17 (94.4%) | 16 (88.9%) | 1.000^ | |
| Positive | 1 (5.6%)a | 2 (11.1%) | ||
| Overall LNM | ||||
| Negative | 9 (47.4%) | 16 (88.9%) | 0.013^ | |
| Positive | 10 (52.6%) | 2 (11.1%) | ||
| Post-resection DOM | ||||
| Negative | 16 (88.9%) | 17 (94.4%) | 1.000^ | |
| Positive | 2 (11.1%) | 1 (5.6%) | ||
IQR interquartile range; PD poor differentiation; LVI lymphovascular invasion; VM vertical margin; SMI Submucosal invasion; LNM lymph node metastasis; DOM distant organ metastasis; NA not available
#Mann–Whitney test
^Fisher’s exact test
aOne case with ER + SR treatment revealed both concurrent and post-resection LNM